Innovent reports Phase 3 trial of arcotatug tavatecan meets OS and PFS endpoints in gastric cancer
Innovent Biologics announced that its international Phase 3 G‑HOPE‑001 study of arcotatug tavatecan in previously treated CLDN18.2‑positive gastric or gastro‑esophageal junction adenocarcinoma met both primary endpoints. Median overall survival was 10.2 months versus 6.9 months for physician’s choice therapy, and median progression‑free survival was 7.1 months versus 3.1 months. The data were presented as a late‑breaking abstract at the 2026 ESMO Congress.
Why it matters
The positive survival data could support regulatory filing and commercial launch outside Greater China, potentially expanding Innovent’s oncology pipeline and revenue. The company’s share price moved modestly higher on the news, indicating market interest.
Key facts
- 1The Phase 3 G‑HOPE‑001 study compared arcotatug tavatecan with physician’s choice therapy in CLDN18.2‑positive advanced gastric cancer. prnewswire.com
- 2Median overall survival was 10.2 months for arcotatug tavatecan versus 6.9 months for the control group, a 43% reduction in risk of death (HR = 0.57, P < 0.0001). prnewswire.com
- 3Median progression‑free survival was 7.1 months for arcotatug tavatecan versus 3.1 months for the control group (HR = 0.45, P < 0.0001). prnewswire.com
- 4Confirmed objective response rate was 37.4% with arcotatug tavatecan versus 7.7% with control therapy. prnewswire.com
- 5Grade ≥ 3 treatment‑related adverse events occurred in 47.4% of patients on arcotatug tavatecan versus 55.9% on control therapy. prnewswire.com
- 6The study results were presented at the 2026 European Society for Medical Oncology (ESMO) Congress. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.